CRYO-CELL LAUNCHES C’ELLE, FIRST-EVER PROPRIETARY MENSTRUAL STEM CELL SERVICE
Posted by Jim H on November 8, 2007
OK, not exactly a local story, but interesting none the less. As some of you may know, I am making a variety of stem cells from afterbirth tissue (placenta, amniotic tissue, Wharton’s jelly, umbilical cord), so why not from menstrual endometrium?
C’elle’s exclusive and revolutionary service provides women with the unique opportunity to collect and preserve vital stem cells that can be harvested from the body’s menstrual fluid during the menstrual cycle. Until now, menstrual blood has typically been discarded as unsanitary waste. However, exciting new research shows that menstrual fluid contains, self-renewing stem cells that can be easily collected, processed and cryo-preserved for potential cellular therapies that may emerge in the future.
I have to give credit to Attila at PIMM for posting this first. Hope he doesn’t mind me lifting a story from him and hopefully this kind of story will spur a bit of renewed interest in my little science experiment.
So, that’s the hype. Here is some of the the science behind it:
Comparative Matrix for Menstrual Stromal Cells and Bone Marrow Mesenchymal Cells
| Cell Characteristics | C’elle (Menstrual Stromal Cells) | BM MSC (Bone Marrow Mesenchymal Cells) |
|---|---|---|
| Cell Collection Procedure | Non-invasive menstrual cup similar to insertion of a tampon | Harvest bone marrow in the OR mobilized adult peripheral blood |
| Cell Morphology | stromal, mesenchymal-like, spindle-shaped in culture | stromal, mesenchymal-like, spindle-shaped in culture (4) |
| Cell Surface Markers associated with mesenchymal cells | CD29, CD44, CD73, CD90, CD105, CD166 MHC I+ MHC II- |
CD29, CD44, CD73, CD90, CD105, CD166 MHC I+ MHC II- (1)(3) |
| Markers associated with embryonic stem cells | SSEA-4, Oct-4 | none |
| Differentiation capability | Neural, Cardiogenic, Chondrogenic, Adipogenic, Osteogenic | Chondrogenic, Adipogenic, Osteogenic (2) |
| MLR | Cells demonstarted a weak stimulatory response which suggests potential use in first-degree relatives | Do not elicit alloreactive lymphocyte proliferative responses (1) |
| Karotype | Normal karyotype | Normal Karyotye (3) |
References:
- Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, & Ringdén O. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 31(10), 890-896.
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411), 143-147.
- Kern S, Eichler H, Stoeve J, Klüter H, Bieback, K. (2006). Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue. Stem Cells, 24(5), 1294 –1301.
- Horwitz, Edwin M. (2007). Report on the Workshop “New Technologies in Stem Cell Research,” Society for Pediatric Research, San Francisco, California, April 29, 2006, Fundamentals of MSC Isolation and Purification.Stem Cells, 25(4), 1070 -1088.
- Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, et al. (2006). Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med, 355(12), 1210-1221.
- Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, et al. (1999). Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med, 5, 309–313.

All content on this site is copyright under Creative Commons Attribution - Share Alike license.










FiberCell Systems
